{"id":"W4324057737","doi":"10.25251/skin.7.supp.140","title":"Safety of tralokinumab in pediatric patients aged 12-17 years with moderate to severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Sanofi Genzyme; Genentech; LEO Pharma; Astellas Pharma; Galderma; Eli Lilly and Company; AstraZeneca; Aimmune Therapeutics; Dermira; UCB Pharma; Regeneron Pharmaceuticals; National Institute for Health and Care Research; Teva Pharmaceutical Industries; European Commission; Sanofi; Amgen; Pfizer; Celgene; GlaxoSmithKline","keywords":"Atopic dermatitis; Medicine; Pediatrics; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001596979,0.0007683061,0.001452716,0.0001518409,0.000295037,0.0006537193,0.0004638362,0.0008913861,0.002481353],"category_scores_gemma":[0.0009937283,0.0002589501,0.001682348,0.0002403086,0.0004253814,0.0004730124,0.0002184692,0.002129291,0.0004459983],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005536948,"about_ca_system_score_gemma":0.001331322,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006876388,"about_ca_topic_score_gemma":0.002282175,"domain_scores_codex":[0.9995635,0.0002197271,0.0000307388,0.00006140784,0.0000543408,0.00007023751],"domain_scores_gemma":[0.9992003,0.0001608255,0.0002755869,0.0000436048,0.00005451593,0.0002651398],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7833569,0.01837086,0.03977193,0.003432496,0.003493562,0.0009102094,0.0003824399,0.001521842,0.01813461,0.0004001338,0.008400709,0.1218243],"study_design_scores_gemma":[0.7157423,0.1833718,0.08493736,0.0003758312,0.002588588,0.001377787,0.0001526111,0.0007521239,0.002836899,0.0001989508,0.007624084,0.00004151383],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9852663,0.009257378,0.0003576514,0.0005889841,0.0001211149,0.00111039,0.001946656,0.00006438115,0.001287325],"genre_scores_gemma":[0.9836157,0.007290559,0.00151351,0.001378597,0.0002232864,0.001975053,0.002406929,0.00003251285,0.001563834],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002481353,"threshold_uncertainty_score":0.00844568,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01381192806385505,"score_gpt":0.2680551295444405,"score_spread":0.2542432014805854,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}